Not Verified

2026 New Multiple Myeloma Education RFP

Johnson & Johnson

The treatment landscape for multiple myeloma (MM) has advanced substantially, moving from conventional chemotherapy to increasingly sophisticated combinations that include proteasome inhibitors, immunomodulatory agents, anti-CD38 monoclonal antibodies, CAR T-cell therapies, and bispecific antibodies. Although these advances have improved survival and broadened treatment options across the disease continuum, relapse remains, and refractory disease, treatment resistance, cumulative toxicity, and access barriers continue to constrain durable disease control. As care becomes more individualized and sequencing decisions more complex, there remains a clear need for novel treatment strategies that can deepen responses, overcome resistance mechanisms, and extend meaningful benefit to patients with heavily pretreated or high-risk disease. Within this context, emerging trispecific antibodies (TsAbs) may represent a next-generation immunotherapeutic approach designed to simultaneously engage multiple tumor antigens and immune effector pathways, with the potential to enhance efficacy while addressing key limitations of existing T-cell–redirecting therapies.

Early clinical data suggests that trispecific antibody approaches may offer meaningful clinical activity in heavily pretreated relapsed/refractory MM, with investigational agents designed to target both BCMA and GPRC5D while engaging CD3-positive T cells. Although these findings remain early and require continued evaluation, they underscore the scientific rationale for BCMA and GPRC5D dual-antigen targeting as a strategy to address tumor heterogeneity, antigen escape, and acquired resistance (van de Donk et al., ASCO 2025 Abstract 7505; Popat et al., EHA 2025 Abstract S100).

At the same time, the rapid pace of innovation is widening educational gaps for hematology/oncology HCPs who must interpret emerging data, anticipate evolving practice implications, and translate novel mechanisms into patient-centered decision-making.

J&J is looking to support independent medical education that will help prepare clinicians to recognize limitations of current MM care, and evaluate emerging trispecific data critically, recognize the unique MOA and scientific rationale for BCMA and GPRC5D dual-antigen targeting, understand where these agents fit in the evolving MM paradigm, create awareness of new and enrolling clinical trials with TsAbs, and support safe, evidence-informed adoption if and when these therapies enter clinical practice.

EDUCATIONAL NEED J&J has determined, through literature searches, insights, and outcomes the following areas of educational needs of healthcare providers:

• Understanding the scientific rationale and mechanistic differentiation of trispecific antibodies in MM, including how BCMA and GPRC5D dual-antigen targeting may overcome disease heterogeneity and resistance mechanisms, enabling greater depth and durability of response relative to existing therapeutic approaches

• Interpreting early-phase efficacy and safety data with appropriate clinical context, including response depth (including MRD), durability, patient population, and limitations of immature evidence.

• Assessing potential implications for treatment sequencing, patient selection, toxicity monitoring, and integration into multidisciplinary care pathways as the evidence base matures.

EXPECTED OUTCOMES AND MEASUREMENT Grant applicants must be willing to adhere to our impact reporting timelines, expecting reports every 90 days. Outcomes plan must include details of the methodology used for determining the impact of the program and should clearly link to the identified practice gap that the educational activity is designed to address. Outcomes methodology must be appropriate to the proposed activity and the intended goals of the project.

EVALUATION CRITERIA Proposals will be evaluated based on:

• Alignment with identified educational gaps and strategic priorities

• Scientific rigor and independence

• Innovation in educational design and learner engagement

• Strength of outcomes framework and measurable impact

BUDGET Grants request must be under $150,000. Priority will be given to lower cost programs that can deliver the education in a timely manner.

AI Based Application Success Predictor

1. Strong alignment with the specific J&J funding opportunity ⭐⭐⭐⭐⭐

This is the most important predictor.

J&J funding is highly program-specific. A successful application should directly match:

The published RFP or challenge
The therapeutic area
The stated educational or scientific gap
The target healthcare population
The specific objectives of the program

For example, J&J's current educational RFPs specify particular disease areas and learning needs rather than accepting unrestricted research proposals.

2. Addressing a significant unmet healthcare need ⭐⭐⭐⭐⭐

Strong proposals demonstrate a clear problem that needs to be solved, such as:

Unmet clinical needs
Treatment gaps
Diagnostic challenges
Patient access problems
Healthcare disparities
Inefficient clinical workflows
Gaps in healthcare-professional knowledge

The stronger and more clearly documented the unmet need, the more compelling the proposal.

3. Innovation and differentiation ⭐⭐⭐⭐⭐

Innovation is particularly important for J&J's technology and entrepreneurship programs.

Competitive projects may involve:

Artificial intelligence
Digital health
Robotics
Surgical technology
Medical devices
Novel therapeutics
Data-driven healthcare
New clinical workflows

The Polyphonic AI Fund for Surgery QuickFire Challenge, for example, is specifically designed to accelerate next-generation AI solutions for surgery.

4. Potential for measurable patient or healthcare impact ⭐⭐⭐⭐⭐

Strong applications clearly explain how the project could:

Improve patient outcomes
Increase treatment quality
Improve diagnosis
Reduce complications
Improve healthcare delivery
Increase access to care
Improve clinician performance

J&J's current corporate strategy emphasizes addressing complex health challenges through medicines and medical technologies.

5. Scientific/clinical credibility and evidence ⭐⭐⭐⭐⭐

Competitive proposals should provide:

Strong evidence supporting the intervention
Relevant clinical or scientific literature
Preliminary data where appropriate
Appropriate methodology
Credible outcome measures

For educational grants, the proposal should clearly establish the identified educational gap, proposed intervention, target audience, and expected outcomes.

6. Clear measurable outcomes ⭐⭐⭐⭐⭐

This is particularly important for J&J educational and implementation grants.

Successful proposals should specify measurable outcomes such as:

Number of healthcare professionals reached
Knowledge improvement
Competence or confidence changes
Changes in clinical practice
Adoption of new workflows
Patient-care improvements
System-level outcomes

For example, a current J&J implementation-science RFP requires reporting on educational reach, learner outcomes, clinician behavior/practice changes, and system/process outcomes.

7. Strong implementation and scalability ⭐⭐⭐⭐☆

J&J favors solutions that can move beyond a small pilot.

Competitive projects demonstrate:

Practical implementation
Scalability
Replicability
Healthcare-system integration
Potential for broader adoption
Sustainability after funding

This is especially relevant to implementation-science and technology programs.

8. Strong multidisciplinary collaboration ⭐⭐⭐⭐☆

Competitive teams may include:

Physicians
Nurses
Pharmacists
Researchers
Engineers
Data scientists
Health-system leaders
Patient representatives
Technology developers

J&J Innovation explicitly works with external innovators and provides resources and collaboration opportunities through its innovation ecosystem.

9. Appropriate target audience and reach ⭐⭐⭐⭐☆

For medical education grants, the application should clearly identify:

Target healthcare professionals
Their knowledge or practice gap
Why the audience needs the intervention
Expected number of participants
Geographic or institutional reach

J&J's educational grants can support activities delivered through live, virtual, and healthcare-team engagement formats.

10. Feasible budget, timeline, and compliance ⭐⭐⭐⭐☆

Successful proposals should have:

Realistic budgets
Appropriate project duration
Clear milestones
Complete documentation
Compliance with the RFP
Appropriate institutional eligibility

For example, J&J's 2026 implementation-science RFP specifies a maximum award of $275,000, a project duration of up to 18 months, and restrictions on certain expenses.

Specialties

Cancer

Oncology

Hematology

Pharmaceuticals

Eligibility Requirements

CME/CE applicants must fall into one of the following categories with a bona fide interest in managing and or treating patients with RRMM: Academic institutions (medicine, pharmacy or nursing), Teaching hospitals, Medical Societies, Professional Associations, Government agencies, medical education companies. Requests must be certified for CME/CE credit(s). Individual physicians or physician owned entities are ineligible to apply. Grants will not be awarded to ex-US entities. This is for US only organizations. APPLICATIONS MUST BE SUBMITTED BY THE ACCREDITED PROVIDER.

It is understood that the accredited provider will comply with all applicable accreditation standards and governing CME/CE requirements, including those of the relevant accrediting body or bodies, as well as applicable federal and state laws and regulations. Applicants will have to identify the accrediting organization(s), credit type(s), and processes that will be used to ensure ongoing compliance throughout the activity lifecycle. You will be required to show proof of accreditation in the required upload section.

Sponsor Details

Sponsor Institute/Organizations: Johnson & Johnson

Sponsor Type: Corporate/Non-Profit

Address: 1 Johnson & Johnson Plaza, New Brunswick, NJ 08933

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity